While no prospective studies have described increased PD1 positivity in these tumors, nor has the therapeutic use of immune checkpoint inhibitors have been reported, multiple case reports have found inflammatory myofibroblastic sarcomas to express PDL1 at a significant level and have notable CD8+ tumor-infiltrating lymphocyte populations [42, 43]. This evidence concerns the gene CD8A and neoplasm.